We have identified ACA in SLE (including anti-BAFF blocking antibodies and anti-IFN-α)18, systemic sclerosis30, and a variety of immunodeficiency disorders18,19,31, suggesting that ACA is probably more common than previously appreciated in immune-mediated diseases. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.